Bio-Technology General Corp. on Monday said it has enteredinto a distribution agreement with VAW-Flusspat ChemieGmbH for BTGC's hyaluronic acid-based ophthalmic product,BioLon.
The German company, which manufactures aluminum andchemical products worldwide, will market BioLon in Germanythrough its wholly owned pharmaceutical and ophthalmiccompany, Pharma-Stulin.
Financial details of the agreement were not disclosed.
The ready-to-use syringe formulation of BioLon is a surgicalaid for use in cataract procedures, intraocular lensimplantation, corneal transplantation and glaucoma, the NewYork company (NASDAQ:BTGC) said.
BTGC said BioLon has been approved in Israel, and has beenlicensed in other European countries. The current Europeanmarket for the product exceeds $100 million, the company said.
(c) 1997 American Health Consultants. All rights reserved.